News
8.10.20

Interview with Reto Naef, CEO of TOPADUR PHARMA AG

 Read the full interview:

Download DocumentDokument herunterladenSwitzerland Global EnterpriseSwitzerland Global Enterprise
1.7.21
Press Release

TOPADUR submits an Orphan Drug Designation application for TOP-N53

TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.

Read more
10.11.20
Press Release

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.

Read more
6.6.24
Press Release

Topadur Pharma AG and Oshen Holdings SA sign a co-development agreement

Topadur Pharma AG and Oshen Holdings SA Partner to Develop a Treatment for Alopecia

Read more

About us

NewsHistoryResearch PartnersCareers

Approach

Topadur CompoundsKey publications

Disease Areas

Lung FibrosisOncologyMedical aestheticsOphthalmologySkin FibrosisWound Healing

Investors

Investors
info@topadur.com+41 44 755 44 66
Topadur Pharma AG | Grabenstrasse 11a, 8952 Schlieren, Switzerland
ImpressumLegal Disclaimer